FindTrial
Sign In

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220584
Enrollment
Unknown
Registered
2008-08-06
Start date
2008-08-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

investigational material(s) Generic name etc : GSK1572932A INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mater

Sponsors

GlaxoSmithKline K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Refer to 'GSK Clinical Study Register'

Exclusion criteria

Exclusion criteria: Refer to 'GSK Clinical Study Register'

Design outcomes

Secondary

MeasureTime frame
Refer to 'GSK Clinical Study Register' Refer to 'GSK Clinical Study Register'—

Primary

MeasureTime frame
Refer to 'GSK Clinical Study Register' Refer to 'GSK Clinical Study Register'—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026